Supernus Pharmaceuticals exec sells $129,676 in stock
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), recently executed a series of stock transactions ...
Nasdaq14d
SUPN Crosses Above Average Analyst Target
In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $39.25, changing hands for $39.41/share. When a stock ...
SUPN stock soars to 52-week high, hits $39.38 amid growth
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) stock has reached a new 52-week high, touching $39.38 as the company continues to show robust performance in the pharmaceutical sector. According to ...
Business Insider15d
Supernus announces U.S. FDA approved an update for label for Qelbree
Supernus (SUPN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to include new pharmacodynamic data in Section 12.2. The ...
Yahoo Finance16d
Supernus Pharmaceuticals, Inc. (SUPN)
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share... MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX ...